Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1887 1
1899 1
1903 2
1918 1
1919 1
1928 2
1929 1
1930 1
1931 3
1932 1
1934 1
1935 2
1936 1
1937 1
1951 4
1952 5
1959 1
1961 1
1964 1
1965 3
1966 1
1967 2
1968 5
1969 1
1970 3
1971 7
1972 6
1973 4
1974 9
1975 14
1976 21
1977 14
1978 14
1979 25
1980 29
1981 40
1982 40
1983 50
1984 42
1985 44
1986 69
1987 92
1988 104
1989 111
1990 114
1991 128
1992 147
1993 173
1994 110
1995 128
1996 103
1997 96
1998 97
1999 109
2000 98
2001 127
2002 132
2003 131
2004 148
2005 175
2006 181
2007 222
2008 238
2009 249
2010 304
2011 356
2012 389
2013 427
2014 470
2015 559
2016 608
2017 613
2018 731
2019 661
2020 814
2021 936
2022 826
2023 856
2024 318

Text availability

Article attribute

Article type

Publication date

Search Results

11,405 results

Results by year

Filters applied: . Clear all
Page 1
Common therapeutic advances for Duchenne muscular dystrophy (DMD).
Salmaninejad A, Jafari Abarghan Y, Bozorg Qomi S, Bayat H, Yousefi M, Azhdari S, Talebi S, Mojarrad M. Salmaninejad A, et al. Int J Neurosci. 2021 Apr;131(4):370-389. doi: 10.1080/00207454.2020.1740218. Epub 2020 Apr 3. Int J Neurosci. 2021. PMID: 32241218 Review.
Background and purpose: Duchenne muscular dystrophy (DMD), a lethal X-linked recessive muscle dystrophy, is resulted in by different mutations including mostly frame-shifting gross deletions and duplications and rarely point mutations in DMD gene. Increasing weaknes …
Background and purpose: Duchenne muscular dystrophy (DMD), a lethal X-linked recessive muscle dystrophy, is resulted in by different …
Exonic rearrangements in DMD in Chinese Han individuals affected with Duchenne and Becker muscular dystrophies.
Ling C, Dai Y, Fang L, Yao F, Liu Z, Qiu Z, Cui L, Xia F, Zhao C, Zhang S, Wang K, Zhang X. Ling C, et al. Hum Mutat. 2020 Mar;41(3):668-677. doi: 10.1002/humu.23953. Epub 2019 Dec 3. Hum Mutat. 2020. PMID: 31705731 Free PMC article.
Exonic deletions and duplications within DMD are the main pathogenic variants in Duchenne and Becker muscular dystrophies (DMD/BMD). ...Furthermore, to unravel the potential mechanism that induced breaks, DMD gene capture and sequencing were performed to iden …
Exonic deletions and duplications within DMD are the main pathogenic variants in Duchenne and Becker muscular dystrophies (DMD …
Pseudoexons of the DMD Gene.
Keegan NP. Keegan NP. J Neuromuscul Dis. 2020;7(2):77-95. doi: 10.3233/JND-190431. J Neuromuscul Dis. 2020. PMID: 32176650 Free PMC article. Review.
The DMD gene is the largest in the human genome, with a total intron content exceeding 2.2Mb. In the decades since DMD was discovered there have been numerous reported cases of pseudoexons (PEs) arising in the mature DMD transcripts of some individuals, eithe …
The DMD gene is the largest in the human genome, with a total intron content exceeding 2.2Mb. In the decades since DMD was dis …
Vascular therapy for Duchenne muscular dystrophy (DMD).
Thapa S, Elhadidy S, Asakura A. Thapa S, et al. Fac Rev. 2023 Feb 21;12:3. doi: 10.12703/r/12-3. eCollection 2023. Fac Rev. 2023. PMID: 36873982 Free PMC article. Review.
Currently, DMD is incurable, and treatment involves the administration of glucocorticoids in order to delay disease progression. ...However, different studies have been carried out to show the relationship between vascular density and impaired angiogenesis in the pathogene …
Currently, DMD is incurable, and treatment involves the administration of glucocorticoids in order to delay disease progression. ...H …
Delandistrogene Moxeparvovec: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Sep;83(14):1323-1329. doi: 10.1007/s40265-023-01929-x. Drugs. 2023. PMID: 37566211 Review.
Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; ELEVIDYS()) is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a gene encoding a micro-dystrophin protein [i.e. a shortened (138 kDa) version of the dystrophin protein expressed in norm …
Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; ELEVIDYS()) is an adeno-associated virus (AAV) vector-based gene therapy de …
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.
Bez Batti Angulski A, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J, Metzger JM. Bez Batti Angulski A, et al. Front Physiol. 2023 Jun 26;14:1183101. doi: 10.3389/fphys.2023.1183101. eCollection 2023. Front Physiol. 2023. PMID: 37435300 Free PMC article. Review.
The first section of the review focuses on DMD and the mechanisms contributing to membrane instability, inflammation, and fibrosis. ...The final section highlights the different therapeutic strategies for DMD currently in clinical trials....
The first section of the review focuses on DMD and the mechanisms contributing to membrane instability, inflammation, and fibrosis. . …
Gene Therapy for Duchenne Muscular Dystrophy.
Elangkovan N, Dickson G. Elangkovan N, et al. J Neuromuscul Dis. 2021;8(s2):S303-S316. doi: 10.3233/JND-210678. J Neuromuscul Dis. 2021. PMID: 34511510 Free PMC article. Review.
Duchenne muscular dystrophy (DMD) is an X-linked, muscle wasting disease that affects 1 in 5000 males. ...In this paper, the authors review the current progress of AAV-microdystrophin gene therapy for DMD and other treatment strategies that may apply to a subset of …
Duchenne muscular dystrophy (DMD) is an X-linked, muscle wasting disease that affects 1 in 5000 males. ...In this paper, the authors …
Exon-Skipping in Duchenne Muscular Dystrophy.
Takeda S, Clemens PR, Hoffman EP. Takeda S, et al. J Neuromuscul Dis. 2021;8(s2):S343-S358. doi: 10.3233/JND-210682. J Neuromuscul Dis. 2021. PMID: 34180420 Free PMC article. Review.
Duchenne muscular dystrophy (DMD) is a devastating, rare disease. While clinically described in the 19th century, the genetic foundation of DMD was not discovered until more than 100 years later. ...Exon skipping to therapeutically restore the frame of an out-of-fra …
Duchenne muscular dystrophy (DMD) is a devastating, rare disease. While clinically described in the 19th century, the genetic foundat …
DMD deletions underlining mild dystrophinopathies: literature review highlights phenotype-related mutation clusters and provides insights about genetic mechanisms and prognosis.
Fortunato F, Tonelli L, Farnè M, Selvatici R, Ferlini A. Fortunato F, et al. Front Neurol. 2024 Jan 15;14:1288721. doi: 10.3389/fneur.2023.1288721. eCollection 2023. Front Neurol. 2024. PMID: 38288333 Free PMC article. Review.
Besides these phenotypes, X-linked dilated cardiomyopathy is also caused by DMD mutations. Males carrying DMD deletions with absent or very mild phenotypes have been sparsely described. We performed a horizon scan on public datasets to enroll males with the above ph …
Besides these phenotypes, X-linked dilated cardiomyopathy is also caused by DMD mutations. Males carrying DMD deletions with a …
Dystrophinopathies.
Darras BT, Urion DK, Ghosh PS. Darras BT, et al. 2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2000 Sep 5 [updated 2022 Jan 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301298 Free Books & Documents. Review.
Females heterozygous for a DMD pathogenic variant are at increased risk for DCM. DIAGNOSIS/TESTING: The diagnosis of a dystrophinopathy is established in a proband with the characteristic clinical findings and elevated CK concentration and/or by identification of a hemizyg …
Females heterozygous for a DMD pathogenic variant are at increased risk for DCM. DIAGNOSIS/TESTING: The diagnosis of a dystrophinopat …
11,405 results
You have reached the last available page of results. Please see the User Guide for more information.